Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma

Clinical and Translational Oncology

Volumn 15, Issue 6, 2013, Pages 460-466

  Figueras, J ^a   Lopez Ben, S ^a   Alsina, M ^a   Soriano, J ^a   Hernandez Yague X ^a   Albiol, M ^a   Guardeno R ^a   Codina Barreras, A ^a   Queralt, B ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Bevacizumab; Metastatic colorectal cancer; Neoadjuvant chemotherapy; Postoperative morbidity; Surgical resection

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL ABSCESS; ADULT; AGED; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HEMOPERITONEUM; HUMAN; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PROSPECTIVE STUDY; SURGICAL MORTALITY; WOUND INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84878691329     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0952-6     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225-249
2. Scheele J, Stangl R, Tendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241-1246
3. Mayo SC, Pawlik TM (2009) Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 3:131-144
4. Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309-318
5. Figueras J, Valls C, Rafecas A et al (2001) Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 88:980-985
6. Stangl R, Tendorf-Hofmann A, Charnley RM et al (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405-1410
7. Figueras J, Torras J, Valls C et al (2007) Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 50:478-488
8. Neeff H, Horth W, Makowiec F et al (2009) Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg 13:1813-1820
9. Shah SA, Haddad R, Al-Sukhni W et al (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 202:468-475
10. Elias D, Liberale G, Vernerey D et al (2005) Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12:900-909
11. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
12. Nordlinger B, Van CE, Rougier P et al (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases treatment group. Eur J Cancer 43:2037-2045
13. Masi G, Loupakis F, Pollina L et al (2009) Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249:420-425
14. Blazer DG III, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344-5351
15. Nordlinger B, Van CE, Gruenberger T et al (2009) Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20:985-992
16. Gruenberger B, Tamandl D, Schueller J et al (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:1830-1835
17. Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761-2767
18. Okines A, Puerto OD, Cunningham D et al (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033-1038
19. D'Angelica M, Kornprat P, Gonen M et al (2007) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:759-765
20. Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254-5260
21. Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106
22. Mahfud M, Breitenstein S, El-Badry AM et al (2010) Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg 34:92-100
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
24. Couinaud C (1954) Anatomic principles of left and right regulated hepatectomy: technics. J Chir (Paris) 70:933-966
25. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-213
26. Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847
27. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2019
28. Baumgaertner I, Ratziu V, Vaillant JC et al (2010) Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review. Bull Cancer 97:559-569
29. Chun YS, Vauthey JN, Boonsirikamchai P et al (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302:2338-2344
30. Cleary JM, Tanabe KT, Lauwers GY et al (2009) Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 14:1095-1105